233 related articles for article (PubMed ID: 33521908)
1. The PrEP Journey: Understanding How Internal Drivers and External Circumstances Impact The PrEP Trajectory of Adolescent Girls and Young Women in Cape Town, South Africa.
O'Rourke S; Hartmann M; Myers L; Lawrence N; Gill K; Morton JF; Celum CL; Bekker LG; van der Straten A
AIDS Behav; 2021 Jul; 25(7):2154-2165. PubMed ID: 33521908
[TBL] [Abstract][Full Text] [Related]
2. HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery.
Celum CL; Delany-Moretlwe S; Baeten JM; van der Straten A; Hosek S; Bukusi EA; McConnell M; Barnabas RV; Bekker LG
J Int AIDS Soc; 2019 Jul; 22 Suppl 4(Suppl Suppl 4):e25298. PubMed ID: 31328444
[TBL] [Abstract][Full Text] [Related]
3. The Community PrEP Study: a randomized control trial leveraging community-based platforms to improve access and adherence to pre-exposure prophylaxis to prevent HIV among adolescent girls and young women in South Africa-study protocol.
Medina-Marino A; Bezuidenhout D; Hosek S; Barnabas RV; Atujuna M; Bezuidenhout C; Ngwepe P; Peters RPH; Little F; Celum CL; Daniels J; Bekker LG
Trials; 2021 Jul; 22(1):489. PubMed ID: 34311754
[TBL] [Abstract][Full Text] [Related]
4. Factors that influence adolescent girls and young women's re-initiation or complete discontinuation from daily oral PrEP use: a qualitative study from Eastern Cape Province, South Africa.
de Vos L; Mudzingwa EK; Fynn L; Atujuna M; Mugore M; Gandhi M; Celum C; Hosek S; Bekker LG; Daniels J; Medina-Marino A
J Int AIDS Soc; 2023 Sep; 26(9):e26175. PubMed ID: 37758649
[TBL] [Abstract][Full Text] [Related]
5. Exploring adolescent girls and young women's PrEP-user profiles: qualitative insights into differentiated PrEP delivery platform selection and engagement in Cape Town, South Africa.
Rousseau E; Sikkema KJ; Julies RF; Mazer K; O'Malley G; Heffron R; Morton JF; Johnson R; Celum C; Baeten JM; Bekker LG
J Int AIDS Soc; 2024 May; 27(5):e26254. PubMed ID: 38695101
[TBL] [Abstract][Full Text] [Related]
6. PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project.
Celum CL; Bukusi EA; Bekker LG; Delany-Moretlwe S; Kidoguchi L; Omollo V; Rousseau E; Travill D; Morton JF; Mogaka F; O'Malley G; Barnabee G; van der Straten A; Donnell D; Parikh UM; Kudrick L; Anderson PL; Haberer JE; Wu L; Heffron R; Johnson R; Morrison S; Baeten JM;
J Int AIDS Soc; 2022 Jul; 25(7):e25962. PubMed ID: 35822945
[TBL] [Abstract][Full Text] [Related]
7. Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial.
Velloza J; Donnell D; Hosek S; Anderson PL; Chirenje ZM; Mgodi N; Bekker LG; Marzinke MA; Delany-Moretlwe S; Celum C
Lancet HIV; 2022 Oct; 9(10):e680-e689. PubMed ID: 36087612
[TBL] [Abstract][Full Text] [Related]
8. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study.
Velloza J; Khoza N; Scorgie F; Chitukuta M; Mutero P; Mutiti K; Mangxilana N; Nobula L; Bulterys MA; Atujuna M; Hosek S; Heffron R; Bekker LG; Mgodi N; Chirenje M; Celum C; Delany-Moretlwe S;
J Int AIDS Soc; 2020 Mar; 23(3):e25463. PubMed ID: 32144874
[TBL] [Abstract][Full Text] [Related]
9. Trajectories of PrEP Adherence Among Young Women Aged 16 to 25 in Cape Town, South Africa.
Stoner MCD; Rucinski KB; Giovenco D; Gill K; Morton JF; Bekker LG; Celum CL; van der Straten A
AIDS Behav; 2021 Jul; 25(7):2046-2053. PubMed ID: 33389323
[TBL] [Abstract][Full Text] [Related]
10. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial.
Celum C; Hosek S; Tsholwana M; Kassim S; Mukaka S; Dye BJ; Pathak S; Mgodi N; Bekker LG; Donnell DJ; Wilson E; Yuha K; Anderson PL; Agyei Y; Noble H; Rose SM; Baeten JM; Fogel JM; Adeyeye A; Wiesner L; Rooney J; Delany-Moretlwe S
PLoS Med; 2021 Jun; 18(6):e1003670. PubMed ID: 34143779
[TBL] [Abstract][Full Text] [Related]
11. A community-based mobile clinic model delivering PrEP for HIV prevention to adolescent girls and young women in Cape Town, South Africa.
Rousseau E; Bekker LG; Julies RF; Celum C; Morton J; Johnson R; Baeten JM; O'Malley G
BMC Health Serv Res; 2021 Aug; 21(1):888. PubMed ID: 34454505
[TBL] [Abstract][Full Text] [Related]
12. Assessing longitudinal patterns of depressive symptoms and the influence of symptom trajectories on HIV pre-exposure prophylaxis adherence among adolescent girls in the HPTN 082 randomized controlled trial.
Velloza J; Hosek S; Donnell D; Anderson PL; Chirenje M; Mgodi N; Bekker LG; Delany-Moretlwe S; Celum C;
J Int AIDS Soc; 2021 Jun; 24 Suppl 2(Suppl 2):e25731. PubMed ID: 34164929
[TBL] [Abstract][Full Text] [Related]
13. Psychosocial determinants of pre-exposure prophylaxis use among pregnant adolescent girls and young women in Cape Town, South Africa: A qualitative study.
Haribhai S; Khadka N; Mvududu R; Mashele N; Bekker LG; Gorbach P; Coates TJ; Myer L; Joseph Davey DL
Int J STD AIDS; 2023 Jul; 34(8):548-556. PubMed ID: 36947792
[TBL] [Abstract][Full Text] [Related]
14. Adaptive HIV pre-exposure prophylaxis adherence interventions for young South African women: Study protocol for a sequential multiple assignment randomized trial.
Velloza J; Poovan N; Ndlovu N; Khoza N; Morton JF; Omony J; Mkwanazi E; Grabow C; Donnell D; Munthali R; Baeten JM; Hosek S; Celum C; Delany-Moretlwe S
PLoS One; 2022; 17(4):e0266665. PubMed ID: 35417485
[TBL] [Abstract][Full Text] [Related]
15. Experiences of oral pre-exposure prophylaxis (PrEP) use disclosure among South African adolescent girls and young women and its perceived impact on adherence.
Giovenco D; Gill K; Fynn L; Duyver M; O'Rourke S; van der Straten A; Morton JF; Celum CL; Bekker LG
PLoS One; 2021; 16(3):e0248307. PubMed ID: 33667264
[TBL] [Abstract][Full Text] [Related]
16. High study participation but diverging adherence levels: qualitatively unpacking PrEP use among adolescent girls and young women over two years in Eastern Cape, South Africa.
Krogstad Mudzingwa E; de Vos L; Atujuna M; Fynn L; Mugore M; Mabandla S; Hosek S; Celum C; Bekker LG; Daniels J; Medina-Marino A
J Behav Med; 2024 Apr; 47(2):320-333. PubMed ID: 38081955
[TBL] [Abstract][Full Text] [Related]
17. The Effect of PrEP Use Disclosure on Adherence in a Cohort of Adolescent Girls and Young Women in South Africa.
Giovenco D; Pettifor A; Powers KA; Hightow-Weidman L; Pence BW; Edwards JK; Gill K; Morton JF; van der Straten A; Celum C; Bekker LG
AIDS Behav; 2022 Apr; 26(4):1007-1016. PubMed ID: 34478015
[TBL] [Abstract][Full Text] [Related]
18. Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial.
Celum CL; Gill K; Morton JF; Stein G; Myers L; Thomas KK; McConnell M; van der Straten A; Baeten JM; Duyver M; Mendel E; Naidoo K; Dallimore J; Wiesner L; Bekker LG
J Int AIDS Soc; 2020 Nov; 23(11):e25636. PubMed ID: 33247553
[TBL] [Abstract][Full Text] [Related]
19. Mandrax use, sexual risk, and opportunities for pre-exposure prophylaxis among out-of-school adolescent girls and young women in Cape Town, South Africa.
Bonner CP; Browne FA; Carney T; Shangase N; Ndirangu JW; Myers B; Wechsberg WM
S Afr Med J; 2022 Apr; 112(5):341-346. PubMed ID: 35587247
[TBL] [Abstract][Full Text] [Related]
20. Adolescent girls and young women's PrEP-user journey during an implementation science study in South Africa and Kenya.
Rousseau E; Katz AWK; O'Rourke S; Bekker LG; Delany-Moretlwe S; Bukusi E; Travill D; Omollo V; Morton JF; O'Malley G; Haberer JE; Heffron R; Johnson R; Celum C; Baeten JM; van der Straten A
PLoS One; 2021; 16(10):e0258542. PubMed ID: 34648589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
